NeOnc Technologies schedules FDA end-of-Phase 1 meeting for brain cancer drug NEO212
Bitget2026/09/28 12:02- NeOnc Technologies scheduled an in-person FDA End-of-Phase 1 meeting for NEO212 on Nov. 17, 2026.
- Phase 1 results were already reported; the company flagged durable disease control in two heavily pretreated brain cancer patients.
- Management framed the outcome as supportive of advancing NEO212 into Phase 2 and pursuing a registrational strategy.
- FDA feedback will guide a revised Phase 2 plan, including patient population and endpoints, with no assurance of accelerated approval.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
The British Pound rallies on a UK growth upgrade and gives more than half back
Only twice in history! S&P 500 equal-weight index is expected to record seven consecutive weeks of decline this week
The S&P 500 Equal Weight Index is expected to fall for a seventh consecutive week. If this downward trend continues through Friday, it will mark only the third time in history that the index has experienced seven straight weeks of decline.
Trump “bites” Powell, demanding his resignation from the Federal Reserve Board, citing severe cost overruns in headquarters renovation.
U.S. President Trump on Wednesday called for former Federal Reserve Chairman Powell to resign from his position as a Fed governor, following an inspector general report on the Federal Reserve headquarters renovation project, which highlighted a series of management issues that led to significant cost overruns.
Crypto prices
More
